LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited, a next-generation point of care diagnostics company, today announced it has commenced commercial shipment of its point of care NT-proBNP ...

Please provide your email address to receive an email when new articles are posted on . Select adults with ischemic heart failure with reduced ejection fraction may derive benefit from an ...

Please provide your email address to receive an email when new articles are posted on . NT-proBNP concentration is a strong predictor of ventricular arrhythmias among people with an implantable device ...

Run on the highly portable LumiraDx Platform, the LumiraDx NT-proBNP test is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes. It is ...